Cipla has reported 19.26% YoY increase in consolidated profits at Rs.422.59 crore for the Q2, against Rs.354.34 crore in the same quarterΒ previous year. Total income...
Cipla’s subsidiary InvaGen Pharmaceuticals Inc has received nod from the US health regulator forΒ Sevelamer Carbonate tablets,Β which are suggested for the control of serum phosphorus in...